Menu Search
Equities

RaySearch Laboratories AB (publ)

RAYBs:EBT

RaySearch Laboratories AB (publ)

Actions
  • Price (SEK)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

  • Revenue in SEK (TTM)1.17bn
  • Net income in SEK175.06m
  • Incorporated1988
  • Employees414.00
  • Location
    RaySearch Laboratories AB (publ)Eugeniavagen 18CSTOCKHOLM 104 30SwedenSWE
  • Phone+46 851053000
  • Fax+46 854506139
  • Websitehttps://www.raysearchlabs.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RAY B:STO since
announced		Transaction
value
Pharmacolog i Uppsala AB-Pharmaceutical AssetDeal completed09 Feb 202409 Feb 2024Deal completed125.54%811.00k
Data delayed at least 15 minutes, as of Nov 21 2024 17:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.